Revance Therapeutics Inc RVNC

NAS: RVNC | ISIN: US7613301099   18:58
3,105 USD (+2,81%)
(+2,81%)   18:58
Grafiek Revance Therapeutics Inc Grafiek Revance Therapeutics Inc

Revance Therapeutics Inc in het nieuws

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

26 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

18 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

29 september 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

17 november 2022 · Nanostics Announces New Member of Board of Directors · Persbericht

5 februari 2022 · Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Revance Therapeutics, Inc. (RVNC) That a Securities Fraud Class Action Lawsuit Has Been Filed On Their Behalf · Persbericht

2 februari 2022 · RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

27 januari 2022 · RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

13 januari 2022 · REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC · Persbericht

13 januari 2022 · Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. · Persbericht

Profiel Revance Therapeutics Inc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Website: www.revance.com

Hoofdzetel: Newark, California vlag Verenigde Staten

CEO: Mark Foley

Werknemers: 630

Aandelen Revance Therapeutics Inc

Beurswaarde: 315,43 miljoen USD

Effecten: 104,45 miljoen

Beta: 2,08

Mijn selecties